Jeffrey A. Meckler's most recent trade in Travere Therapeutics Inc was a trade of 19,500 Stock option (right to buy) done . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 87,500 (0%) | 0% | 0 | Common Stock | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 4,750 | 0 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 3,750 | 0 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 1,563 | 0 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 1,500 | 0 | - | - | sStock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 1,250 | 0 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Apr 2025 | 813 | 0 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 42,553 | 42,553 | - | - | Common Stock Warrants | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 1.18 per share. | 25 Nov 2024 | 42,553 | 202,859 | - | 1.2 | 50,000 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 40,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Sale of securities on an exchange or to another person at price $ 14.06 per share. | 30 Sep 2024 | 40,000 | 81,000 (0%) | 0% | 14.1 | 562,324 | Common Stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.48 per share. | 30 Sep 2024 | 40,000 | 121,000 (0%) | 0% | 10.5 | 419,200 | Common Stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 1.83 per share. | 08 Aug 2024 | 84,932 | 160,306 | - | 1.8 | 155,001 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2024 | 84,932 | 84,932 | - | - | Common Stock Warrants | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 81,000 (0%) | 0% | 0 | Common Stock | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 1.90 per share. | 18 Nov 2022 | 9,600 | 75,374 | - | 1.9 | 18,240 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 1.76 per share. | 18 Nov 2022 | 400 | 65,774 | - | 1.8 | 705 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 2.80 per share. | 08 Sep 2022 | 10,308 | 65,374 | - | 2.8 | 28,862 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 2.57 per share. | 06 Sep 2022 | 8,632 | 55,066 | - | 2.6 | 22,184 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 2.44 per share. | 06 Sep 2022 | 1,060 | 46,434 | - | 2.4 | 2,586 | Common stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 2.63 per share. | 06 Jun 2022 | 19,727 | 45,374 | - | 2.6 | 51,882 | Common stock |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 70,000 (0%) | 0% | 0 | Common Stock | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 5.82 per share. | 18 Nov 2021 | 11,187 | 25,647 | - | 5.8 | 65,108 | Common Stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 7.00 per share. | 14 Sep 2021 | 12,000 | 14,460 | - | 7 | 84,000 | Common Stock |
| Indaptus Therapeutics Inc | Jeffrey A. Meckler | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2021 | 375,000 | 375,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Jeffrey A. Meckler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 67,000 (0%) | 0% | 0 | Common Stock |